Biocon's Semglee gets USFDA approval; first interchangeable biosimilar product in US

“It is a milestone achievement for both Biocon Biologics and our partner Viatris. This will allow pharmacy level substitution and thereby provide convenient and affordable access to Semglee, a quality Biosimilar Insulin Glargine,” Biocon Biologics, Executive Chairperson, Kiran Mazumdar-Shaw said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3iXS2G8
via IFTTT